There were 676 press releases posted in the last 24 hours and 156,690 in the last 365 days.

Immutep Commences Patient Dosing in Additional TACTI-mel Cohort

/EIN News/ -- SYDNEY, Australia, March 21, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) has announced the initiation of patient dosing in the new cohort of the TACTI-mel (Two ACTive Immunotherapies in melanoma) Phase 1 clinical trial.  This clinical study is evaluating the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with pembrolizumab (KEYTRUDA®) in unresectable or metastatic melanoma patients in Australia.

The additional cohort consists of six patients that will receive 30 mg of efti in combination with pembrolizumab starting at cycle one of pembrolizumab. Patients will be treated for up to 12 months. Yesterday the first patient in this cohort received their first dose of the two drugs. Safety assessment is the main objective of this study.

“This additional cohort of the ongoing TACTI-mel clinicial trial is very important to the clinical development of efti, especially in the light of our new collaboration study announced on 12th of March 2018, as we are now dosing efti at cycle one in combination with KEYTRUDA® with the highest dose and for a 12-month duration,” said Dr. Frédéric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer.  “We look forward to presenting additional data from the TACTI-mel study during the middle of this calendar year as we hope it will further support our hypothesis that combining an antigen-presenting cell activator (efti) with a checkpoint inhibitor (KEYTRUDA®) results in a therapeutic synergy and a potential benefit over checkpoint inhibitor monotherapy.”

About Immutep

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the U.S. 

For further information please visit www.immutep.com or contact:

U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com

Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com

Distribution channels: Technology


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.